-
Something wrong with this record ?
Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC
O. Fiala, P. Hosek, M. Pesek, J. Finek, J. Racek, P. Stehlik, O. Sorejs, M. Minarik, L. Benesova, A. Celer, I. Nemcova, R. Kucera, O. Topolcan,
Language English Country Greece
Document type Journal Article
NLK
Free Medical Journals
from 2004 to 2 years ago
Open Access Digital Library
from 2004-01-01
- MeSH
- Survival Analysis MeSH
- ErbB Receptors genetics MeSH
- Erlotinib Hydrochloride adverse effects blood therapeutic use MeSH
- Exanthema chemically induced MeSH
- Humans MeSH
- Lung Neoplasms blood drug therapy genetics MeSH
- Carcinoma, Non-Small-Cell Lung blood drug therapy genetics MeSH
- Disease-Free Survival MeSH
- Antineoplastic Agents adverse effects blood therapeutic use MeSH
- Diarrhea chemically induced MeSH
- Retrospective Studies MeSH
- Neoplasm Staging MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Erlotinib is a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR); it is used in the treatment of advanced non-small cell lung cancer (NSCLC). We focused on the role of serum concentration of erlotinib and its association with outcome and toxicity in patients with advanced NSCLC harbouring the wild-type EGFR gene or squamous histology. PATIENTS AND METHODS: Clinical data of 122 patients were analyzed. Serum samples were collected within four weeks after the initiation of treatment. RESULTS: There was no significant association of erlotinib concentration with PFS nor OS (p=0.352 and p=0.6393). Significant associations of erlotinib concentration with grade of skin rash and diarrhoea (p<0.0001 and p<0.0001) were found. Skin rash and diarrhoea were significantly associated with PFS (p=0.0338 and p=0.0001) and OS (p=0.0064 and p=0.0353). CONCLUSION: Erlotinib concentration was not associated with outcome. Erlotinib concentration was associated with occurrence and severity of skin rash and diarrhoea; the outcome was associated with erlotinib toxicity.
Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Center for Applied Genomics of Solid Tumours Genomac Research Institute Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016264
- 003
- CZ-PrNML
- 005
- 20180515103951.0
- 007
- ta
- 008
- 180515s2017 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/anticanres.12102 $2 doi
- 035 __
- $a (PubMed)29061834
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic fiala.o@centrum.cz. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
- 245 10
- $a Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC / $c O. Fiala, P. Hosek, M. Pesek, J. Finek, J. Racek, P. Stehlik, O. Sorejs, M. Minarik, L. Benesova, A. Celer, I. Nemcova, R. Kucera, O. Topolcan,
- 520 9_
- $a BACKGROUND: Erlotinib is a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR); it is used in the treatment of advanced non-small cell lung cancer (NSCLC). We focused on the role of serum concentration of erlotinib and its association with outcome and toxicity in patients with advanced NSCLC harbouring the wild-type EGFR gene or squamous histology. PATIENTS AND METHODS: Clinical data of 122 patients were analyzed. Serum samples were collected within four weeks after the initiation of treatment. RESULTS: There was no significant association of erlotinib concentration with PFS nor OS (p=0.352 and p=0.6393). Significant associations of erlotinib concentration with grade of skin rash and diarrhoea (p<0.0001 and p<0.0001) were found. Skin rash and diarrhoea were significantly associated with PFS (p=0.0338 and p=0.0001) and OS (p=0.0064 and p=0.0353). CONCLUSION: Erlotinib concentration was not associated with outcome. Erlotinib concentration was associated with occurrence and severity of skin rash and diarrhoea; the outcome was associated with erlotinib toxicity.
- 650 _2
- $a protinádorové látky $x škodlivé účinky $x krev $x terapeutické užití $7 D000970
- 650 _2
- $a nemalobuněčný karcinom plic $x krev $x farmakoterapie $x genetika $7 D002289
- 650 _2
- $a průjem $x chemicky indukované $7 D003967
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a erlotinib $x škodlivé účinky $x krev $x terapeutické užití $7 D000069347
- 650 _2
- $a exantém $x chemicky indukované $7 D005076
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory plic $x krev $x farmakoterapie $x genetika $7 D008175
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a erbB receptory $x genetika $7 D066246
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hosek, Petr $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Pesek, Milos $u Department of Pneumology, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Finek, Jindrich $u Department of Oncology and Radiotherapeutics, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Racek, Jaroslav $u Institute of Clinical Biochemistry and Haematology, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Stehlik, Pavel $u Institute of Clinical Biochemistry and Haematology, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Sorejs, Ondrej $u Department of Oncology and Radiotherapeutics, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Minarik, Marek $u Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic. Department of Analytical Chemistry, Faculty of Sciences, Charles University, Prague, Czech Republic.
- 700 1_
- $a Benesova, Lucie $u Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic.
- 700 1_
- $a Celer, Adam $u Department of Oncology and Radiotherapeutics, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Nemcova, Ivana $u Department of Oncology and Radiotherapeutics, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Kucera, Radek $u Department of Immunochemistry, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Topolcan, Ondrej $u Department of Immunochemistry, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 37, č. 11 (2017), s. 6469-6476
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29061834 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180515104124 $b ABA008
- 999 __
- $a ok $b bmc $g 1299888 $s 1013104
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 37 $c 11 $d 6469-6476 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- LZP __
- $a Pubmed-20180515
